MedTrace Logo

Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention

NCT06692140 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3150

Last updated 2024-12-09

No results posted yet for this study

Summary

The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention

Conditions

Interventions

DEVICE

Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

DEVICE

PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Lisette O Jensen · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-16
Primary Completion
2028-07-01
Completion
2032-07-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06692140 on ClinicalTrials.gov